Trial Profile
A Pilot Study of Genasense (G3139, Oblimersen Sodium, Bcl-2 Antisense Oligonucleotide), Fludarabine and Rituximab in Previously Treated Subjects With Chronic Lymphocytic Leukemia.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Fludarabine (Primary) ; Oblimersen (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors Genta (CEASED)
- 04 Nov 2011 Planned end date changed from 1 Sep 2009 to 1 Sep 2010 as reported by ClinicalTrials.gov.
- 02 Jun 2009 Trial phase changed from II to I/II as reported by ClinicalTrials.gov.
- 02 Jun 2009 Planned end date (1 Sep 2009) added as reported by ClinicalTrials.gov.